Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
2001.
Current Awareness in Geriatric Psychiatry.
International Journal of Geriatric Psychiatry,
Vol. 16,
Issue. 12,
p.
1184.
Leverenz, James B
and
McKeith, Ian G
2002.
Dementia with Lewy bodies.
Medical Clinics of North America,
Vol. 86,
Issue. 3,
p.
519.
Assal, Frédéric
and
Cummings, Jeffrey L.
2002.
Neuropsychiatric symptoms in the dementias.
Current Opinion in Neurology,
Vol. 15,
Issue. 4,
p.
445.
Ballmaier, M
Casamenti, F
Scali, C
Mazzoncini, R
Zoli, M
Pepeu, G
and
Spano, P.F
2002.
Rivastigmine antagonizes deficits in prepulse inhibition induced by selective immunolesioning of cholinergic neurons in nucleus basalis magnocellularis.
Neuroscience,
Vol. 114,
Issue. 1,
p.
91.
Herrmann, Nathan
2002.
Pharmacotherapy for Alzheimerʼs disease and other dementias.
Current Opinion in Psychiatry,
Vol. 15,
Issue. 4,
p.
403.
Rot, U.
Kobal, J.
Sever, A.
Pirtošek, Z.
and
Mesec, A.
2002.
Rivastigmine in the treatment of Huntington's disease.
European Journal of Neurology,
Vol. 9,
Issue. 6,
p.
689.
Swanberg, Margaret M.
and
Cummings, Jeffrey L.
2002.
Benefit-Risk Considerations in the Treatment of Dementia with Lewy Bodies.
Drug Safety,
Vol. 25,
Issue. 7,
p.
511.
Robert, Philippe
2002.
Understanding and Managing Behavioural Symptoms in Alzheimer's Disease and Related Dementias: Focus on Rivastigmine.
Current Medical Research and Opinion,
Vol. 18,
Issue. 3,
p.
156.
Bullock, R
2002.
THE CLINICAL BENEFITS OF RIVASTIGMINE MAY REFLECT ITS DUAL INHIBITORY MODE OF ACTION: AN HYPOTHESIS.
International Journal of Clinical Practice,
Vol. 56,
Issue. 3,
p.
206.
Gabelli, C.
2003.
Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions.
Current Medical Research and Opinion,
Vol. 19,
Issue. 2,
p.
69.
Minett, Thaís S. C.
Thomas, Alan
Wilkinson, Lucy M.
Daniel, Sarah L.
Sanders, Jonathan
Richardson, Jonathan
Littlewood, Elizabeth
Myint, Pat
Newby, Jane
and
McKeith, Ian G.
2003.
What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia.
International Journal of Geriatric Psychiatry,
Vol. 18,
Issue. 11,
p.
988.
Farlow, Martin R.
2003.
Update on Rivastigmine.
The Neurologist,
Vol. 9,
Issue. 5,
p.
230.
Burn, David J.
and
McKeith, Ian G.
2003.
Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease.
Movement Disorders,
Vol. 18,
Issue. S6,
p.
72.
Fernandez, Hubert H
Trieschmann, Martha E
and
Friedman, Joseph H
2003.
Treatment of Psychosis in Parkinson???s Disease.
Drug Safety,
Vol. 26,
Issue. 9,
p.
643.
Fernandez, Hubert H
Wu, Chuang-Kuo
and
Ott, Brian R
2003.
Pharmacotherapy of dementia with Lewy bodies.
Expert Opinion on Pharmacotherapy,
Vol. 4,
Issue. 11,
p.
2027.
Grossberg, George T
2003.
Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:.
Current Therapeutic Research,
Vol. 64,
Issue. 4,
p.
216.
2003.
The Neuropsychiatry of Alzheimer's Disease and Related Dementias.
p.
117.
Gustavson, Andrew R.
and
Cummings, Jeffrey L.
2003.
Cholinesterase Inhibitors in Non-Alzheimer Dementias.
Journal of the American Medical Directors Association,
Vol. 4,
Issue. 6,
p.
S165.
Gustavson, Andrew R.
and
Cummings, Jeffrey L.
2003.
Cholinesterase Inhibitors in Non-Alzheimer Dementias.
Journal of the American Medical Directors Association,
Vol. 4,
Issue. 6,
p.
S165.
Bosboom, J. L. W.
Stoffers, D.
and
Wolters, E. Ch.
2003.
Advances in Research on Neurodegeneration.
Vol. 65,
Issue. ,
p.
185.